Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription

Posted June 30, 2008

Roche decision denies cancer drug to Britons
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Member Program Contributor

Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.

Posted June 19, 2008

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Member Program Contributor

Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

Posted June 19, 2008

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Analysis of: Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
Author: GLG Member Program Contributor

"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...

Posted June 9, 2008

Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Member Program Contributor

Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...

Posted June 6, 2008

Potential lung cancer epidemic looming in Asia
Analysis of: Potential lung cancer epidemic looming in Asia | www.pipelinereview.com
Author: GLG Member Program Contributor

Drugs are relatively ineffective for NSCLC due to the following. Firstly, stage III is the main target of chemotherapy, while being very heterogenous combination of T and N criteria. Outcome results, therefore, are controversial. Next, lung cancer is more than many other malignancies is caused by an...

Posted June 6, 2008

Transgene's TG4010 vaccine has a fairy elegant two-gene design. It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer. More mature survival data will be ready by year's end. Phase III study is being planned. ...

Posted June 5, 2008

Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor

The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.

Posted June 4, 2008

This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)

Posted June 4, 2008

Positive data on Antisoma’s ASA404 presented at ASCO
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Member Program Contributor

That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.

Posted June 4, 2008

Mixed Outcomes in Laparoscopy for Prostates
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Member Program Contributor

Laparoscopic prostatectomy has become increasingly common. Previously published data supports the advantages of this approach cited here, such as shorter hospital stay and decreased blood loss. However, there are concerns long term raised here, including questions regarding oncologic efficacy. ...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 724

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-05T01:45:16.907

All GLG News Analyses Filed Under: Oncology

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare